YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Novartis Takes $665m Bid for Selexys


September 21, 2012 | In addition to $23 million of Series A financing, Selexys Pharmaceuticals Corp. of Oklahoma City has struck an agreement with Novartis that could lead to the company's acquisition for up to $665 million. Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease. Tulsa World
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.